Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors

Herbert, GS; Vreeland, TJ; Clifton, GT; Greene, JM; Jackson, DO; Hardin, MO; Hale, DF; Berry, JS; Nichol, P; Yin, S; Yu, XZ; Wagner, TE; Peoples, GE

Herbert, GS (reprint author), San Antonio Mil Med Ctr, Dept Surg, 3551 Roger Brooke Dr, San Antonio, TX 78234 USA.

VACCINE, 2018; 36 (23): 3247

Abstract

Introduction: Tumor vaccines use various strategies to generate immune responses, commonly targeting generic tumor-associated antigens. The tumor lysa......

Full Text Link